RAF Trial logoRAF TrialRecruiting nowCommon Femoral Artery steno-occlusive disease; Peripheral Arterial Disease; Chronic Limb-Threatening Ischaemia; Lower limb claudication

A RAndomised controlled trial assessing the clinical and cost-effectiveness of Endovascular vs. Open revascularisation for common Femoral artery steno-occlusive disease. The RAF Trial.

Recruitment

0 of 504

24 NHS sitesAge 18+

Participants

504

target

Sites

24

NHS

Age

18+

years

Duration

4years

Sept 2025 – Nov 2029

Status

Recruiting

ISRCTN12861037

Overview

About this trial

The RAF trial is a two-arm prospective, superiority, multicentre, randomised controlled trial comparing open surgery versus endovascular treatment for steno-occlusive common femoral artery (CFA) disease. It will recruit 504 adults with chronic limb-threatening ischaemia (CLTI) or severe lifestyle-limiting lower limb claudication from at least 24 NHS hospitals across the UK. Participants will be randomised 1:1 to open surgery or endovascular treatment and followed for a minimum of 12 months. The primary outcome is a composite of all-cause death and/or reintervention (major amputation or lower limb revascularisation) assessed as time-to-first-event. The trial includes an internal pilot phase, a QuinteT Recruitment Intervention (QRI) communication study, a qualitative process evaluation, and a health economic evaluation.

Why this trial is needed

No randomised trial has previously compared open surgery versus endovascular treatment for common femoral artery steno-occlusive disease. A national survey of 121 NHS clinicians confirmed equipoise among surgeons and radiologists, with 90% feeling there is an urgent need for this RCT and 57% indicating they would randomise patients. The James Lind Alliance Priority Setting Partnership identified this as a top research priority. Observational data show similar patency rates but are biased and do not prospectively assess clinically meaningful outcomes such as amputation rates or reinterventions.

Outcomes

What the trial measures

Primary outcome

Composite of death (all-cause) and/or reintervention (major amputation or lower limb revascularisation) over a minimum of one year (time-to-event analysis). Major amputation is defined as any amputation above the level of the ankle joint in the ipsilateral lower limb. Revascularisation is defined as any arterial revascularisation in the ipsilateral lower limb.

Secondary outcomes

  • Mortality (all cause)
  • Hospital admissions (including reason for admission)
  • Reinterventions (including nature of reintervention)
  • All lower limb amputations (minor and major i.e. below and above ankle joint)
  • Quality-of-life using EQ-5D-5L tool
  • Quality adjusted life years (QALYs)
  • Healthcare resource-use and costs
  • Incremental cost per life year gained and per QALY gained

Eligibility

Who can take part

Age18+ years

Can take part if

  • Age 18 years or older
  • CLTI (rest pain and/or tissue loss) or severe life-style limiting claudication (Rutherford Stage 3 or higher or Fontaine Stage IIb or higher)
  • Patient deemed suitable for CFA open surgery or endovascular treatment by the treating clinicians (pragmatic design)

Cannot take part if

  • Asymptomatic PAD
  • Pregnancy

Participation

What taking part involves

Intervention

Open surgical revascularisation of the common femoral artery compared to endovascular treatment (minimally invasive) of the common femoral artery. The exact configuration of open surgery and the exact type of endovascular procedure (any angioplasty device, stent, vessel preparation strategy, or other adjunct endovascular procedure) will be decided locally. Inflow and outflow procedures are permitted in both arms at clinician discretion.

Procedures

  • Screening and eligibility assessment
  • Written informed consent (face-to-face, electronic via REDCap, or telephone)
  • Baseline assessment
  • Randomisation 1:1 to open surgery or endovascular treatment
  • Open surgical revascularisation of the CFA (with or without inflow/outflow procedures) or endovascular treatment of the CFA (with or without inflow/outflow procedures)
  • Follow-up assessments for death, amputation, reintervention, hospital admissions, cardiovascular events, and quality-of-life
  • EQ-5D-5L questionnaire completion
  • Review of medical notes for healthcare resource use
  • Remote telephone follow-up (centrally) to capture missing information
  • Optional linkage to NHS routine clinical datasets
  • QuinteT Recruitment Intervention including audio-recorded recruitment consultations and semi-structured interviews
  • Qualitative process evaluation interviews at two time points (post-treatment and approximately 12 months later) for a subset of patients at three centres

Visit schedule

  • Baseline Visit (Day 0)
  • Review of Clinical Events at Day of Discharge, Day 30, Month 6, Month 12, and annually thereafter until Month 36
  • EuroQOL EQ-5D-5L Questionnaire at Baseline and Months 6, 12, 24, and 36

Where

Participating sites (1)

At least 24 NHS hospital locations in the UK (England, Scotland and Wales) including Leicester, Hull, and London as named centres for qualitative sub-study

Support

Funding

NIHR Health Technology Assessment Programme (Reference: NIHR167450)

← Browse all trials

View patient-friendly version of this trial →